Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24051718 | 0.86 | RAB9A (0.59) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL9097718 | 0.85 | RAB9A (0.61) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL31018405 | 0.84 | RAB9A (0.54) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL31018387 | 0.82 | RAB9A (0.55) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL31018389 | 0.79 | CYP1A2 (0.53) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL1502654 | 0.79 | RAB9A (0.51) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL691101 | 0.78 | RAB9A (0.64) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL13144514 | 0.77 | MAPT (0.70) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL29936118 | 0.77 | KDM1A (0.43) | RAB9AMAPTNPC1ALDH1A1GAA | |
| SCHEMBL914552 | 0.77 | RAB9A (0.68) | RAB9AMAPTNPC1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-20250368614-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-04 | — | — | US | disclosed |
| EP-4654969-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-03 | — | — | EP | disclosed |
| EP-4654971-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-03 | — | — | EP | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| EP-4573088-A1 | HETEROCYCLE RBM39 MODULATORS | Recursion Pharmaceuticals, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-119630658-A | Heterocyclic RBM39 modulators | 递归医药公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2024159067-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024159081-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-08-02 | — | — | WO | disclosed |
| US-20240092770-A1 | Heterocycle RMB39 Modulators | RECURSION PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-20150266890-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-24 | — | — | US | disclosed |
| CN-104902885-A | Sulfamoyl-arylamides and their use as medicaments for the treatment of hepatitis B | JANSSEN R & D IRELAND | 2015-09-09 | — | — | CN | disclosed |
| CN-104812743-A | Sulfamoyl-arylamides and their use as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC IE | 2015-07-29 | — | — | CN | disclosed |
| EP-2890688-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2015-07-08 | — | — | EP | disclosed |
| EP-2890375-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014033170-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014033176-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-03-06 | — | — | WO | disclosed |
| US-7897776-B2 | Sulfonamide containing compounds for treatment of inflammatory disorders | SALUTRIA PHARMACEUTICALS LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090270454-A1 | Sulfonamide containing compounds for treatment of inflammatory disorders | CRABTREE ACQUISITION CO, LLC | 2009-10-29 | — | — | US | disclosed |
| WO-2008130718-A1 | SULFONAMIDE CONTAINING COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | ATHEROGENICS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368614-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | YAP1, YES1, TEAD2 | RAB9A 189/4885MAPT 279/4885NPC1 1647/4885 |
| US-20150266890-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | RAB9A 3544/4885MAPT 4375/4885NPC1 1927/4885 |
| US-20090270454-A1 | Sulfonamide containing compounds for treatment of inflammatory disorders | STS, SULT2A1, CYP2S1 | RAB9A 3488/4885MAPT 4492/4885NPC1 2308/4885 |
| US-20240092770-A1 | Heterocycle RMB39 Modulators | PRMT9, RCC2, RBBP9 | RAB9A 37/4885MAPT 3912/4885NPC1 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.